Identifying important mutations in non-coding regions of multiple myeloma
Official title: Identifying and characterizing functional noncoding mutations in multiple myeloma
Funded at Hackensack University Medical Center · NIH-11056029 · Data updated 2026-11-12
This study is looking at changes in certain parts of DNA that might help us understand how multiple myeloma, a type of blood cancer, develops, and it’s for patients who want to learn more about what might be happening in their bodies and how we can improve treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hackensack University Medical Center NIH-funded |
| Lab location | 1 site (Hackensack, United States) |
| Project start | April 13, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $706,026 |
| NIH project number | 5R01CA270252-03 |
| Project ID | NIH-11056029 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with multiple myeloma, particularly those with specific molecular subtypes of the disease.
✕Less likely to help
Patients with non-cancerous conditions or those without a diagnosis of multiple myeloma may not benefit from this research.
What this research studies
This research investigates mutations in non-coding regions of DNA that may influence the development of multiple myeloma, a type of blood cancer. By using advanced techniques like whole-genome sequencing and bisulfite sequencing, the study aims to identify specific mutations that affect gene regulation. Patients' tumor samples will be compared to their non-cancerous blood cells to pinpoint mutations that could play a role in cancer progression. The goal is to better understand how these mutations contribute to the disease and potentially identify new targets for treatment.
Why it matters
Potential benefit: If successful, this research could lead to new insights into the genetic factors driving multiple myeloma, potentially improving treatment strategies.
How similar studies have gone: Previous research has shown promise in identifying functional mutations in non-coding regions in other cancers, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Hackensack University Medical Center
Hackensack, United States Active
Researchers
- Principal investigator: Tycko, Benjamin — Hackensack University Medical Center
- Study coordinator: Tycko, Benjamin
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.